Garikapati KK, Kiran AVVVR, Thaggikuppe Krishnamurthy P, S T N, B B, Nagappan K. Quantification of rosiglitazone in rat plasma and tissues via LC-MS/MS - method development, validation, and its application in pharmacokinetic and tissue distribution studies.
Biomed Chromatogr 2022;
36:e5326. [PMID:
34993979 DOI:
10.1002/bmc.5326]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 12/23/2021] [Accepted: 12/27/2021] [Indexed: 11/05/2022]
Abstract
A bioanalytical method for the quantification of rosiglitazone on rat plasma and tissues (adipose tissue, heart, brain, bone, and kidney) using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was developed and validated. Chromatographic separation was achieved on Gemini C18 column (50mm x 4.6mm, 3μm) using mobile phase consists of 10mM ammonium formate (pH 4.0) and acetonitrile (10:90, v/v) at a flow rate of 0.8 mL/min and injection volume of 10μL (Internal standard - Pioglitazone). LC-MS detection was performed with multiple reaction monitoring mode (MRM) using target ions at m/z→358.0 and m/z → 357.67 for rosiglitazone and pioglitazone (IS) respectively. The calibration curve showed a good correlation coefficient (r2 ) over the concentration range of 1-10000 ng/mL. The mean percentage recoveries of rosiglitazone were found to be over the range of 92.54-96.64 % with detection and lower quantification limit of 0.6 ng/mL and 1.0 ng/mL, respectively. The developed method was validated as per USFDA guidelines and successfully utilized to measure rosiglitazone in plasma and tissue samples. Further, the developed method can be utilized for validating specific organ targeting delivery systems of rosiglitazone in addition to conventional dosage forms.
Collapse